TG Therapeutics Inc
TGTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.75B
Close$
$0.44
99.3% downside
Current Fair Value
99.3% downsideOvervalued by 99.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $9.75 Billion |
|---|---|
| Enterprise Value | $10.10 Billion |
| Earnings per Share | $3.1 |
| Beta | 1.81 |
| Outstanding Shares | 140,786,274 |
Return
| Return on Equity | 18.54% |
|---|---|
| Return on Assets | 6.66% |
| Return on Invested Capital | 14.85% |
Valuation & Multiples
| P/E Ratio | 86.6 |
|---|---|
| PEG | -100.92 |
| Price to Sales | 10.75 |
| Price to Book Ratio | 16.13 |
| Enterprise Value to Revenue | 11.25 |
| Enterprise Value to EBIT | 51.08 |
| Enterprise Value to Net Income | 95 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 1.36 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 9, 2026
EPS
$0.35
Est. $0.36Revenue
$259.94 M
Est. $245.47 MNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$0.56
Consensus analyst estimateRevenue Estimate
$290.22 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 1.00, calls and puts are about even.
| Put/Call Ratio | 1.0000▲ 38.70% |
|---|---|
| Total Calls | 18,000▼ 99.29% |
| Total Puts | 18,000▼ 98.85% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.04%▼ 66.41% |
|---|---|
| Total Invested | $1.03B▼ 83.35% |
| Investors Holding | 200▼ 265.00% |
About TG Therapeutics Inc
CEO: Michael Weiss
